NCT07892755Recruiting
Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese Populations
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
Endometrial cancer is one of the most common gynecological malignancies, and its incidence is rising. Currently, there is a lack of highly effective and non-invasive screening methods. Liquid biopsy, which analyzes cell-free DNA (cfDNA) in the blood, has emerged as a promising approach for early cancer detection. This observational study aims to develop and evaluate a non-invasive blood test to screen for early-stage endometrial cancer and to distinguish between benign and malignant endometrial lesions. This study plans to enroll 512 female participants, divided into three groups: 216 patients with stage I-IV endometrial cancer, 80 patients with atypical endometrial hyperplasia (a precancerous condition), and 216 healthy controls. We will collect peripheral blood samples from all participants and perform low-pass whole-genome sequencing (WGS) on the extracted plasma cfDNA. By analyzing specific DNA features (such as DNA fragment patterns, end motifs, and copy number variations) and using artificial intelligence (machine learning), we will build a predictive model. This study hopes to establish a more effective, non-invasive early screening strategy to improve the clinical diagnosis of endometrial cancer in the Chinese population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 512 (estimated)
- First submitted
- 18 Oct 2026
- Start date
- 10 Aug 2026
- Primary completion date
- 9 Aug 2027
- Lead sponsor
- Guizhou Provincial People's Hospital
- Diseases
- Endometrial cancer, Childhood cancers
- NCT number
- NCT07892755
What you commit to
- Study type: Observational
- Planned participants: 512
- From 10 Aug 2026 to the primary completion date, 9 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnant women.
- Current diagnosis of tumors other than endometrial cancer or a history of previous tumors.
- Received any form of tumor treatment prior to blood draw, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
- Current febrile illness, or acute/inflammatory disease requiring internal medical treatment within 14 days prior to blood draw.
- Organ transplant recipients or previous recipients of allogeneic bone marrow or stem cell transplants.
- Poor health status or unsuitable for blood draw.
- Any other clinically significant disease or condition that, in the investigator's opinion, may affect protocol compliance, affect the subject's ability to sign informed consent, or make the subject unsuitable for this clinical study.
Who the study is looking for
- Female, aged \> 18 years.
- Participants fully understand the study requirements and sign the written informed consent.
- Cohort A (Endometrial Cancer): Patients with histologically and/or cytologically confirmed stage I-IV endometrial cancer; comprehensive clinical and pathological information is available.
- Cohort B (Atypical Hyperplasia): Patients diagnosed with atypical endometrial hyperplasia; comprehensive clinical and pathological information is available.
- Cohort C (Healthy Control): Healthy female subjects with no tumors or suspicious nodules confirmed by systematic examination.
Age in the registry: - to 18 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guizhou Provincial People's Hospital Coordinator of this site? Confirm its status | Guiyang | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.